Key facts
- Neuro42’s last known valuation is $135.0M.
- It has raised $30.0M across 2 recorded rounds; the latest was Early Stage VC ($15.6M) in Sep 2024.
- Notable investors include Keiretsu Forum, ShangBay Capital, Blacktop Capital, Frederic Moll, K2X — 12 tracked in total.
- Neuro42 has filed 2 Form Ds with the SEC, most recently Sep 2024 ($15.6M sold to 85 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Neuro42
Funding rounds
2 roundsAbout Neuro42
Developer of portable magnetic resonance imaging machines designed to offer diagnosis and interventions for neurological conditions. The company's device focuses on imaging for triaging, screening, diagnosing, and intervening in the treatment of various brain conditions that range from traumatic injury to epilepsy and tumors, enabling patients with a point-of-care shift for those who have experienced a stroke and facilitating the use of direct robotic interventions outside of the traditional magnetic resonance suite.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2020
- Employees
- 31
- Website
- neuro42.ai/
- Ownership
- Privately Held (backing)
Neuro42 doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Neuro42 shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Neuro42 in its N-PORT filings yet. We sweep new filings monthly.